Figures computed from official regulatory filings — .
Analysttarget 61 USD (+2033233%) · consensus 4/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0.06% · institutions 0.46% · short 34.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Aditxt, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
37 buys16 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Takeover Time 2026 LLC | Sell | $68.4K | SEC |
| HRT FINANCIAL LPtrack record | Sell | $92.2K | SEC |
| HRT FINANCIAL LPtrack record | Buy | $95.4K | conv 38 | SEC |
| HRT FINANCIAL LPtrack record | Sell | $40.7K | SEC |
| DRW Securities, LLC | Sell | $1K | SEC |
| HRT FINANCIAL LPtrack record | Buy | $29.6K | conv 38 | SEC |
| HRT FINANCIAL LPtrack record | Buy | $68K | conv 38 | SEC |
| BANK OF AMERICA CORP /DE/track record | Sell | $0.2 | SEC |
| BANK OF AMERICA CORP /DE/track record | Buy | $0 | conv 18 | SEC |
| BANK OF AMERICA CORP /DE/track record | Buy | $0 | conv 19 | SEC |
| BANK OF AMERICA CORP /DE/track record | Buy | $0 | conv 18 | SEC |
| BANK OF AMERICA CORP /DE/track record | Buy | $0 | conv 18 | SEC |
| BANK OF AMERICA CORP /DE/track record | Buy | $0 | conv 18 | SEC |
| HRT FINANCIAL LPtrack record | Sell | $39.7K | SEC |
| HRT FINANCIAL LPtrack record | Buy | $13.8K | conv 52 | SEC |
| HRT FINANCIAL LPtrack record | Buy | $69.8K | conv 38 | SEC |
| HRT FINANCIAL LPtrack record | Sell | $29K | SEC |
| Gong Sandie | Sell | $6.9K | SEC |
| HRT FINANCIAL LPtrack record | Buy | $64.1K | conv 38 | SEC |
| HRT FINANCIAL LPtrack record | Sell | $45.6K | SEC |
| HRT FINANCIAL LPtrack record | Sell | $8.2K | SEC |
| HRT FINANCIAL LPtrack record | Sell | $1.1K | SEC |
| HRT FINANCIAL LPtrack record | Sell | $3.6K | SEC |
| HRT FINANCIAL LPtrack record | Buy | $24.1K | conv 52 | SEC |
| Brady Brian Michael | Sell | $1.8 | SEC |